Clinical trials: Ovary Disease
Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor
Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer
This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy (SBRT) in treating patients with metastatic or recurrent ovarian cancer or primary peritoneal cancer.
- Conditions
- Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Malignant Tumor of Peritoneum, Stage IV Ovarian Epithelial Cancer
- Trial name
- NCT01494012
- Testing
- stereotactic body radiation therapy, positron emission tomography, computed tomography
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Stanford University
Advanced Solid Tumors
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2).
- Trial name
- NCT05941507
- Testing
- LCB84, Anti-PD-1 monoclonal antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 300 people
- Sponsor
- LigaChem Biosciences, Inc.
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, Depression, Anxiety
Research on Risk Factors and Interventions of Polycystic Ovary Syndrome Complicated With Depression and Anxiety
The current study intends to establish a prediction method and evaluation system for polycystic ovary syndrome (PCOS) complicated with affective disorder, such as depression and anxiety, through the epidemiological investigation.
- Trial name
- PCOS (NCT04984070)
- Testing
- Oral Contraceptives, Combined, Metformin Pill, lifestyle intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Solid Tumors, Ovarian Cancer
A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
ALM201/0001 is a Phase I, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics (PK) of ALM201. Part 1 will be a dose-escalation study.
- Trial name
- NCT03427073
- Testing
- ALM201
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Almac Discovery
Ovary Cancer
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer
The R0 resection rate in neoadjuvant chemotherapy for advanced ovarian cancer remains below 50%, indicating unmet clinical needs.
- Trial name
- NCT07667751
- Testing
- Sunitinib、Olaparib、Tolilizumab
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Bai-Rong Xia
Ovarian Cancer
Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging Algorithm
Ovarian cancer is relatively rare but fatal with an annual incidence rate of 11.8 per 100 000 and a high mortality-to-incidence ratio of >0.6.
- Trial name
- NCT04214782
- Testing
- Artificial Intelligence Enabled Transvaginal Ultrasound Imaging algorithm
- Volunteers
- 10,000 people
- Sponsor
- Tongji Hospital
Advanced Solid Tumor, Ovarian Cancer
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
- Trial name
- NCT05103683
- Testing
- TORL-1-23
- Where
- 14 sites in United States, South Korea
- Volunteers
- 90 people
- Sponsor
- TORL Biotherapeutics, LLC
Ovary Cancer
An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery
This study looks to enroll subjects with ovarian cancer who will be having standard of care surgery to remove ovarian cancer tumors.
- Trial name
- NCT03011320
- Testing
- EC1456, 99mTc-Etarfolatide
- Where
- 2 sites in United States, Canada
- Volunteers
- 3 people
- Sponsor
- Endocyte
Ovarian Carcinoma
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
Preclinical studies showed that metronomic chemotherapy can induce tumor regression secondary to apoptosis of the tumor blood vessels. This effect was increased by combining metronomic chemotherapy with anti-angiogenic drugs.
- Trial name
- NCT01175772
- Testing
- Cytophosphan, Celecoxib, Methotrexate
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- HaEmek Medical Center, Israel
PROC, Platinum Resistant Ovarian Cancer
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants with advanced or metastatic solid tumors.
- Conditions
- PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
- Trial name
- NCT07470853
- Testing
- HWK-016, MUCIN-16-targeted ADC, Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 265 people
- Sponsor
- Whitehawk Therapeutics, Inc.
Epithelial Ovarian Cancer
Determining Prognostic Immune Markers in Patients With Ovarian Cancer
The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).
- Trial name
- IMPrOVE (NCT03862677)
- Testing
- No intervention
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Leiden University Medical Center
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Ovarian Cancer
NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)
The primary objective of this extension protocol is to evaluate the early safety of a new schedule of NGR-hTNF given weekly, instead of every 3 or 4 weeks, in a cohort of 12 patients randomized to the experimental arm A, as…
- Trial name
- NCT03804866
- Testing
- NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin
- Where
- 4 sites in Italy
- Volunteers
- 14 people
- Sponsor
- AGC Biologics S.p.A.
Ovarian Cancer, Intraperitoneal Chemotherapy
Intensive Intraperitoneal Therapy in Advanced Ovarian Cancer
Clinicians postulate that it may be interesting to combine the two IntraPeritoneal (IP) treatments associated with a significant improvement of OC overall survival i.e.
- Trial name
- INTENS-IP (NCT04282356)
- Testing
- Intraperitoneal chemotherapy during surgery
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Primary Ovarian Insufficiency
Efficacy, Safety, and Tolerability of Higher Doses Estrogen Therapy in Women With Premature Ovarian Insufficiency
The goal of this study is to assess the effects of higher doses versus standard hormone therapy on quality of life (QoL), symptoms due to estrogen deficiency, and bone health in women with premature ovarian insufficiency (POI).
- Trial name
- NCT05737329
- Testing
- Transdermal estradiol gel 0.1% 1.5mg/ day, Transdermal estradiol gel 0.1% 2.0mg/ day
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare
Polycystic Ovary Syndrome (PCOS), Insulin Resistance
SCUBE Proteins in Polycystic Ovary Syndrome (IPSOS)
This study investigates circulating levels of SCUBE-1 and SCUBE-3 proteins in women with polycystic ovary syndrome (PCOS) compared with healthy controls.
- Trial name
- IPSOS (NCT07396402)
- Testing
- Blood Sample Collection for SCUBE-1 and SCUBE-3 Measurement
- Where
- Italy
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Relapsed Ovarian Cancer
Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment
This study is a Phase II single-arm, open label, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma .
- Trial name
- NCT06081595
- Testing
- Fluzoparib, Apatinib
- Volunteers
- 54 people
- Sponsor
- Jin Li
Ovarian Cancer, Epithelial
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian…
- Trial name
- NCT05422183
- Testing
- Envafolimab, Lenvatinib, VP-16
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zhongda Hospital
Advanced Solid Tumors
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
This is a Phase I, dose escalation, safety study of OSI-930 and Erlotinib in cancer tumors.
- Trial name
- NCT00603356
- Testing
- OSI-930 and erlotinib
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Astellas Pharma Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.